Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  BioPharma  /  Immutep De nieuwe australische Galapagos ??

Ontvang nu dagelijks onze kooptips!

word abonnee

BioPharma« Terug naar discussie overzicht

Immutep De nieuwe australische Galapagos ??

582 Posts
Pagina: «« 1 2 3 4 5 6 ... 30 »» | Laatste | Omlaag ↓
  3. Pensioen planner 8 november 2020 20:23
    ASX Announcement
    AT SOCIETY FOR IMMUNOTHERAPY OF CANCER 2020 ANNUAL MEETING
    IMMUTEP’S TACTI-002 DATA TO BE PRESENTED
    SYDNEY, AUSTRALIA – 3 November 2020 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or
    “the Company”),
    a biotechnology company developing novel immunotherapy treatments for cancer and
    autoimmune diseases, is pleased to announce more mature interim data from its phase II TACTI-002 study of eftilagimod alpha (“efti”) has been accepted as a late breaker poster presentation and poster walk for highly
    scored abstracts at the Society for Immunotherapy of Cancer (SITC
    2020 Annual Meeting,
    which is taking place as a virtual event from 9-14 November, US Eastern
    Time (US EST).
    SITC is the world’s leading member society of medical professionals dedicated to advancing cancer immunotherapy and biological therapy. Its Annual Meeting is a multidisciplinary educational and interactive
    conference focused on improving cancer patient outcomes.
    Immutep’s Poster Presentation:
    ) 35th Anniversary Standard
    Abstract title: A Phase II study (TACTI-002) of eftilagimod alpha (a soluble LAG-3 protein) with pembrolizumab in PD-L1 unselected patients with metastatic non-small
    cell lung (NSCLC) or head and neck carcinoma (HNSCC)
    Abstract #: 790
    Date & time: Presenter:
    Monday 9 November 2020, 8am US EST
    Dr Matthew Krebs, The Christie NHS Foundation Trust, Manchester, UK
    Immutep will make the poster presentation available on its website following its publication at SITC 2020.
    About TACTI-002
    TACTI-002 is being conducted in collaboration with Merck & Co., Inc., Kenilworth, NJ, USA (known as “MSD” outside the United States and Canada). It is evaluating the combination of efti with MSD’s KEYTRUDA® (or
    pembrolizumab, an anti-PD-1 therapy) in up to 109 patients.
    About Immutep
    Immutep is a globally active biotechnology company that is a leader in the development of LAG-3
    immunotherapies for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Immutep is listed on the Australian Securities Exchange (IMM) and the NASDAQ
    (IMMP) in the United States.
    Immutep’s current lead product candidate is eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3Ig fusion protein which is a first-in-class antigen presenting cell (APC) activator and is being explored in cancer and infectious disease.
    Immutep Limited, Level 12, 95 Pitt Street, Sydney NSW 2000 ABN: 90 009 237 889

    Additional LAG-3 products, including antibodies, for immune response modulation in autoimmunity and cancer are being developed by Immutep’s large pharmaceutical partners. Immutep is also developing an agonist of LAG-3 (IMP761) for autoimmune disease.
    Further information can be found on the Company’s website www.immutep.com or by contacting:
    Australian Investors/Media:
    Catherine Strong, Citadel-MAGNUS
    +61 (0)406 759 268; cstrong@citadelmagnus.com
    U.S. Media:
    Tim McCarthy, LifeSci Advisors
    +1 (212) 915.2564; tim@lifesciadvisors.com
    This announcement was authorised for release by the Chief Executive Officer of Immutep Limited.
    Immutep Limited, Level 12, 95 Pitt Street, Sydney NSW 2000 ABN: 90 009 237 889
  4. Pensioen planner 8 november 2020 20:24
    quote:

    joostUSA schreef op 8 november 2020 16:11:

    Leuk, heb hem op de watchlist gezet, vanavond even onderzoek doen. Gekocht op de ASX of de Nasdaq? Behoorlijk verschil in transactie kosten via de Giro, Ndq is behoorlijk goedkoper.
    Ik heb ze op ASX gekocht.
    Maar volgens mij maakt het niet veel uit..

    Groet,
    PP
582 Posts
Pagina: «« 1 2 3 4 5 6 ... 30 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Indices

AEX 874,75 +0,08%
EUR/USD 1,0725 +0,26%
FTSE 100 8.076,91 +0,45%
Germany40^ 18.012,70 -0,42%
Gold spot 2.327,76 +0,50%
NY-Nasdaq Composite 15.712,75 +0,10%

Stijgers

Flow T...
+4,77%
UNILEV...
+4,60%
NX FIL...
+2,93%
Fugro
+1,75%
ForFar...
+0,63%

Dalers

ADYEN NV
-14,11%
WDP
-4,77%
VIVORY...
-4,69%
IMCD
-2,51%
BESI
-2,30%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!